Radiofrequency Ablation in Relieving Pain in Patients With Bones Metastases
Metastatic Cancer, Pain
About this trial
This is an interventional supportive care trial for Metastatic Cancer focused on measuring bone metastases, pain
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed bone metastases Pain refractory to non-opioid analgesic medication and radiotherapy OR Patient is considered a poor candidate for opioid analgesics or radiotherapy Initial worst pain score within the past 24 hours at least 4 on a scale of 0-10 Tumors deemed accessible for radiofrequency ablation No evidence of impending fracture in weight-bearing bones (more than 50% loss of cortical bone) Tumors must be more than 1 cm from critical structures including: Spinal cord, brain, or other critical nerve structures Large abdominal vessel (e.g., aorta or inferior vena cava) Bowel or bladder PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life expectancy: More than 2 months Hematopoietic: Platelet count at least 75,000/mm3 Hepatic: INR less than 1.5 Renal: Not specified Other: Not pregnant or nursing Negative pregnancy test PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy Surgery: Not specified Other: At least 3 days since prior aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs No concurrent anticoagulants
Sites / Locations
- Northwestern Memorial Hospital
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Massachusetts General Hospital Cancer Center
- Mayo Clinic Cancer Center
- University of Texas - MD Anderson Cancer Center
- St. Luke's Medical Center